Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. The company focuses on developing and commercializing precision medicines that address the root cause of hyperphagia and severe obesity linked to impairments in the melanocortin-4 receptor (MC4R) pathway. Headquartered in Boston, Massachusetts, Rhythm has successfully commercialized its lead product, IMCIVREE (setmelanotide), for the treatment of certain rare genetic disorders of obesity. The company maintains a robust clinical pipeline, exploring additional indications for setmelanotide as well as developing next-generation MC4R agonists, including bivamelagon and RM-718, to expand treatment options for patients with hypothalamic obesity and other rare metabolic conditions.